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論    文    の    要    旨 
 
Introduction 
  Boron neutron capture therapy (BNCT) is an external beam radiation treatment that is based on the capture reaction 
between thermal neutrons and nonradioactive isotope 10B atoms, producing high linear-energy-transfer (LET) α particles 
and 7Li nuclei with an average total kinetic energy of 2.34 MeV. These high LET particles are reported to traverse 5–9 μm, 
similar to the diameter of one cell. Thus, cytotoxic effects are believed to occur in 10B atom-containing tumor cells only 
after thermal neutron irradiation, without additional damage to the adjacent healthy tissues. Along the development of 
accelerator, which is smaller and more convenient to be set up in hospital compared with nuclear reactor, BNCT will 
potentially become a generic cancer therapy in the near future.  
  One of the most important issues of BNCT is to develop 10B agents leading satisfactory therapeutic effect without strong 
adverse effect. However, owing to the low molecular weight (LMW), currently clinical applied 10B agents are rapidly 
cleared from the circulatory system after administration. Thus, a high dose is generally required to achieve the effective 10B 
concentration (>20 ppm) in tumors. Furthermore, the nonspecific dispersion of LMW 10B agents throughout the entire body 
also tends to increase the risk of both systemic toxicity and adverse effects during the thermal neutron irradiation.  
  To improve drug accumulation and retention tendency in the tumor site, nanoscale materials used to deliver 10B agents for 
BNCT have attracted much attention. Because they are only several tens of nanometers in size and are covered by 
biocompatible polymers such as poly(ethylene glycol) (PEG) as a shell, nanoparticles possessing high colloidal stability and 
non-biofouling characteristics tend to accumulate in tumor tissues as a result of the poorly aligned neovascularization and 
lack of effective lymphatic drainage in these areas, which is referred to as the enhanced permeability and retention (EPR) 
effect. So far, most of the reported works that have used this strategy were focused on physically encapsulating 
boron-cluster compounds in liposomes. However, because the encapsulation of these kinds of LMW compounds increases 
the osmotic pressure of liposome interior, encapsulated boron-cluster compounds tend to leak from the liposome into the 
blood stream thus leading to a limited therapeutic effect.  
  It was reported previously that inflammation of tumor microenvironment contributes to resistance to radiotherapy. Nuclea 
factor-kappa B (NF-κB), which is one of transcription factors, plays a pivotal role in regulation of this kind of 
inflammation-based resistance and blocking of NF-κB to enter nucleus inhibited the adaptive radio resistance of tumor cells. 
Furthermore, during BNCT, γ-ray emission due to the neutron capture reaction occurring in the tumor tissue also causes 
adverse effects, such as inflammation, by generating a large amount of reactive oxygen species (ROS). Therefore, 
elimination of these original and BNCT-generated ROS is anticipated to increase the radio sensitivity of tumor cells and 
suppress ROS-induced adverse effects. 
  In this work, we synthesized a new anionic block copolymer, PEG-b-poly((closo-dodecaboranyl)thiomethylstyrene) 
(PEG-b-PMBSH), by introducing a negatively charged boron cluster, BSH, to the side chain of the 
poly(chloromethylstyrene) (PCMS) segment in the prepolymer PEG-b-PCMS. Because BSH is a hydrophilic and 
low-toxicity compound, it is much more suitable as a boron source than the hydrophobic carborane used in our previous 
work. The total molecular weight of this block copolymer is approximately 7,000 Da; thus, it is anticipated to be excreted 
by renal filtration after the disintegration of the polyion complex (PIC) micelle, which was prepared in this study. Our 
original nitroxide-radical-containing cationic block copolymer, 
PEG-b-poly(4-(2,2,6,6-tetramethylpiperidine-N-oxyl)aminomethylstyrene) (PEG-b-PMNT) was also synthesized by 
introducing 4-amino-2,2,6,6-tetramethylpiperidine-N-oxyl (4-amino-TEMPO) as the side chain of the PCMS segment, since 
the nitroxide radical in the TEMPO moiety strongly eliminates ROS. When the anionic PEG-b-PMBSH is coupled with the 
cationic PEG-b-PMNT, boron-cluster-containing redox nanoparticles (BNPs) are obtained via PIC formation. Note that 
because the BSH is conjugated to the block copolymer through a covalent bond, it is hard to leak BSH from the nanoparticle. 
The high charge densities and hydrophobic polystyrene segments are expected to increase the colloidal stability under 
physiological conditions, without complicated chemical cross-linking or conjugation reactions. PEG-b-PMNT had been 
used as an antioxidant polymer drug (redox nanoparticle, RNPN) and proved effective for oxidative stress-related diseases 
such as cerebral and renal ischemia-reperfusion injuries and cancer. We have previously confirmed that RNPN worked well 
to inhibit NF-κB expression in nucleus of tumor tissue and suppressed the inflammation. Considering of this mechanism, 
suppression of NF-κB activation might also improve therapeutic effect of BNPs because of PEG-b-PMNT as a counterpart 
of the BNP. Thus, these BNPs are anticipated to be a high-performance nanomedicine for BNCT, with the ability to lower 
the adverse effects by scavenging ROS as well as by effectively damaging the tumor cells.  
 
Results 
  The boron-cluster-conjugated anionic block copolymer PEG-b-PMBSH was synthesized for the first time by introducing 
a clinically applied 10B agent (BSH) to the polystyrene segments of PEG-b-PCMS. The BNPs were prepared by mixing 
PEG-b-PMBSH and PEG-b-PMNT in phosphate buffer solution with various concentrations of boron and various molar 
ratios of polyanion/polycation. An almost completely unimodal distribution of nanoparticles (of several tens of nanometer 
size) was observed by dynamic light scattering (DLS). The zeta potential of this complex was close to zero, suggesting 
complete shielding of the charges of BSH by the PEG outer layer.  
    To obtain further information on the colloidal stability of the BNPs, after incubation in mice plasma solution or 
phosphate-buffered saline (PBS) solution containing 10% fetal bovine serum (FBS) for 48 h at 37 °C. Neither aggregates 
nor disassembly of the BNPs was observed, confirming their highly stable character even in serum proteins. Considering the 
results above, BNPs have very high colloidal stability affording them for the further in vitro and in vivo study. 
  The cytotoxicity of the BNPs was evaluated by WST-8 cell proliferation assay kit using mouse colorectal carcinoma cells 
(C-26, mouse cell line derived from rectal cancer, BALB/c strain). BNPs did not show cytotoxicity at all in a relative high 
concentration of 10B. It may be because of their neutral surface and high colloidal stability. 
  We evaluated the cellular uptake of BNPs in both the C-26 cell line and human aortic endothelial cell line (HAEC) and 
calculated the uptake ratio. The LMW 10B agents BPA-fructose complex and BSH were used as controls. Because BSH is a 
divalent anion, it is barely able to access the cellular membrane, resulting in low cellular uptake. No tumor selectivity for 
the internalization of BSH was observed. On the other hand, with the BPA-fructose complex, the tumor cells showed 
elevated and selective internalization of BPA, which is ascribed to the preferred cellular uptake (especially by tumor cells) 
of amino acid derivatives of BPA. The selective internalization of BPA to tumor cells was 2.5-fold higher than to normal 
cells. The preferential internalization of BNPs to tumor cells relative to normal HAECs was 3.3-fold, much higher than that 
of BPA. This is probably due to the enhanced solubilization of the nanoparticles to the membrane lipid bilayer through the 
PEG fusion process. PEG-modified derivatives are widely known to undergo enhanced cellular uptake in many types of 
cancer cells.  
  The accumulation tendency of boron species in the tumor environment is quite important in practical treatment in vivo. 
Thus, a pharmacokinetics study of the BNPs was performed to investigate their blood circulation tendency and tumor 
accumulation character in C-26 tumor-bearing BALB/c male mice. The 10B concentration in circulating blood decreased 
slowly after intravenous (i.v.) injection (via the tail vein) of BNPs. The long circulation tendency of BNPs is important to 
increase their accumulation in the tumor site, because repeated access to the tumor neovascular wall increases leakage in the 
area via the EPR mechanism. The 10B concentration in tumor tissues reached high level at 48 h after administration, and 
remained at this level until 72 h without significant change. In contrast, the LMW BSH was excreted rapidly after 1 h, and 
almost disappeared in the blood circulation after 24 h without specific tumor accumulation. Such increased accumulation, 
prolonged retention in tumor environment, and selective internalization to tumor cells of the BNPs might improve the 
therapeutic effect of thermal neutron treatment, which is described later.  
  Thermal neutron irradiation was carried out to evaluate the therapeutic effect of the BNPs in C-26 tumor-bearing BALB/c 
male mice. BPA-fructose complex, RNPN, and PBS administration followed by thermal neutron irradiation, and PBS 
administration without irradiation were used as controls. In both groups of BNPs administration, the tumor/blood (T/B) ratio 
of 10B concentration (one of the most important factors) was higher than that in the BPA-fructose complex group. A higher 
T/B ratio implies lower adverse damage to the circulation system and normal tissues during irradiation, because of the lower 
amount of 10B atoms in the blood vessels. 
  PBS-treated group showed slight tumor suppression effect after thermal neutron irradiation compared to the unirradiated 
group, which is probably because of an effect of γ ray mixed in the neutron ray from the nuclear reactor. It is interesting to 
note that the BNP-treated group, with much lower 10B concentration in the tumor, suppressed tumor growth to the same 
degree as the BPA-fructose complex group.  
  The therapeutic effect of BNPs on a relatively large tumor model was then investigated. That is, the 10B agents were 
administered to tumors of an average volume of 340 mm3. All 10B samples were administered to tumor-bearing mice by i.v. 
injection via the tail vein 3 d before the thermal neutron irradiation, except for BSH, which was given 1 h before the 
irradiation because of its rapid excretion. In the BNP-treated group, 5 ppm of 10B was observed in the tumor tissues, 
whereas 15 ppm accumulated in the tumor tissues administered BSH. Almost no tumor growth was observed in the 
BNP-treated group, regardless of the low 10B concentration in the tumor tissues. It is again observed that saline-treated 
group showed a slight suppression effect of tumor growth after thermal neutron irradiation, because of γ ray irradiation. The 
relative body weight of the mice in the BNP-treated group kept increasing after a transient period, indicating that BNPs did 
not have significant systemic toxicity.  
  BNCT is considered as a novel cancer therapeutic with low adverse effects, because the thermal neutron ray is a benign 
beam source that does not cause the direct strong ionization damage to healthy cells, which is commonly observed in 
radiotherapy using x ray and γ ray. However, γ rays are still emitted by the neutron capture nuclear reaction in tumor cells 
during the irradiation and cause oxidative damage to healthy tissues by generating ROS, increasing the leukocyte level. 
Both the BPA-fructose complex and PBS-treated groups presented significantly high leukocyte levels after irradiation, 
compared with the control group and the PBS-treated group without irradiation (PBS-C). On the other hand, the BNP and 
RNPN-treated groups presented almost the same leukocyte level as the controls, indicating that the ROS scavenger might 
work to suppress the increasing in leukocyte level. Let us emphasize again that the BNPs worked well to suppress tumor 
growth despite the very low 10B concentration in tumor tissues, even though it eliminated generated ROS, indicating that the 
observed suppression of tumor progression was not governed by ROS generation but rather by the direct attack of the 
generated active species (such as α ray and 7Li nuclei) by the nuclear reaction between the BNPs and thermal neutrons. The 
generated ROS cause inflammation and adverse effects to the entire body. On the basis of these results, it is concluded that 
the ROS scavenging ability installed in the BNPs helped to enhance the therapeutic effect and suppress inflammation, which 
is one of the main adverse effects of BNCT caused by ionization during the irradiation. 
 
Discussion 
  With BNPs, a low 10B concentration in tumor tissues led to an ideal tumor suppression effect. On the other hand, 
satisfactory therapeutic effect in the BSH-treated group was not observed. The higher and specific cellular uptake into tumor 
cells of BNPs might contribute effectively to this satisfactory therapeutic effect. In addition, the high tumor retention of 10B 
atoms during the 40 min irradiation in the BNP-treated group might guarantee the required 10B concentration in tumor tissue, 
even with the lower initial boron dose. In the case of LMW 10B agents (BPA and BSH), the 10B atoms in tumor tissue kept 
decreasing as a result of rapid excretion, and thus a higher boron dose might be required. From these results, BNPs indeed 
damaged the tumor cells, and suppressed the tumor growth and metastasis, as well as suppressed adverse effects through 
ROS scavenging activity after thermal neutron irradiation. We strongly believe that the BNP is a quality candidate as a 
boron delivery system for satisfactory BNCT performance. 
審    査    の    要    旨 
〔批評〕 
  
論文審査及び質疑応答に関して、合成、基礎物理化学特性、生理学的特性、実用化に至る広
範な議論に的確に回答し、ホウ素中性子補足療法に対する治療効果の向上及び副作用の低減に
成功した結果を確認し、本論文の新しい材料の設計、特性評価及び治療への応用における成果が評価
された。 
 
 
〔最終試験結果〕 
 平成 28年 2月 12日、数理物質科学研究科学位論文審査委員会において審査委員の全員出席のもと、
著者に論文について説明を求め、関連事項につき質疑応答を行った。その結果、審査委員全員によっ
て、合格と判定された。 
 
〔結論〕 
 上記の論文審査ならびに最終試験の結果に基づき、著者は博士（工学）の学位を受けるに十分な資格
を有するものと認める。 
